Skip to content
Medical Health Aged Care

Cure Brain Cancer Foundation Unveils Fellowship Awardees

Cure Brain Cancer Foundation 2 mins read

Pioneering Innovations in the Fight Against Cancer

SYDNEY, AUSTRALIA / ACCESSWIRE / June 30, 2023 / Cure Brain Cancer Foundation (CBCF) is pleased to announce the highly anticipated recipients of this year's prestigious Early Career Fellowships. This unrivaled funding opportunity is set to empower researchers, propelling them closer to breakthrough discoveries in the battle against brain cancer.

Designed to fuel cutting-edge research initiatives, CBCF research grants are championing advancements that hold the potential to revolutionize survival outcomes for individuals challenged by this formidable disease. From project grants to life-changing fellowships, this comprehensive program undertakes an unwavering commitment to addressing the urgent needs of the brain cancer community.

This round of CBCF grant funding is the first time ever that CBCF will be awarding two exceptional individuals: Andrew Garvie of Monash University and Dr. Alexander Davenport of Walter and Eliza Hall Medical Institute. CBCF grant monies, totaling over $1.4 million in the last 21 months, and the awarding of not one but two Early Career Fellowships in 2023, demonstrate the Foundation's commitment to supporting and empowering talented individuals in the field of cancer research.

"Today, we celebrate exceptional minds and groundbreaking projects that have the power to change lives," remarked Lance Kawaguchi, Chief Executive Officer for the Cure Brain Cancer Foundation. "These grants stand as a testament to our unwavering dedication to funding groundbreaking research that makes tangible progress in the relentless pursuit of a cure for cancer."

With this year's grant fellowship awards, innovative research initiatives will receive the vital resources they need to forge ahead with their life-saving endeavors for a duration of three years. By providing crucial funding and support for this extended period, CBCF remains at the vanguard of the fight against cancer, driving tangible impact and instilling hope in the hearts of patients and their families.

About Cure Brain Cancer Foundation

Cure Brain Cancer Foundation is an Australia-based non-profit organization that is working globally to rapidly improve disease survival through funding innovative brain cancer research. It is the largest dedicated funder of brain cancer research in Australia and has invested over $30 million into clinical trials and pre-clinical efforts across pediatric and adult brain cancers. The Foundation's mission is to unite the brain cancer community and rapidly increase patient survival and quality of life. For more information, visit https://www.curebraincancer.org.au/.

Contact Information

Melinda Koski
MK Public Relations
[email protected]

SOURCE: Cure Brain Cancer Foundation

.


View source version on accesswire.com:
https://www.accesswire.com/764864/Cure-Brain-Cancer-Foundation-Unveils-Fellowship-Awardees

More from this category

  • Medical Health Aged Care
  • 04/03/2026
  • 08:56
Monash University

Monash University and Seaport Therapeutics Awarded up to $21 Million AUD from ARPA-H to Advance GlyphCeleTM, the First Oral Therapeutic Designed to Restore Gut Lymphatic Function

ARPA-H award supports the development of an oral prodrug, based on the Glyph™ platform initially developed at the Monash Institute of Pharmaceutical Sciences (MIPS), to address dysfunctional gut lymphatics linked to metabolic disease and pancreatic cancer. Monash University has announced the award of support from the Advanced Research Projects Agency for Health (ARPA-H) to advance an oral prodrug of celecoxib – using the GlyphTM platform and designed to deliver therapy directly to the gut lymphatics – aiming to improve lymphatic function and advance the treatment of metabolic disease and pancreatic cancer by directly addressing local inflammation and lymphatic dysfunction. The…

  • Medical Health Aged Care, Women
  • 04/03/2026
  • 06:00
Australia New Zealand Gynaecological Oncology Group (ANZGOG)

STRIVE clinical trial now available in Aotearoa New Zealand to improve outcomes in vulvar cancer

MEDIA RELEASE: Wednesday,4March2025 The Australian New Zealand Gynaecological Oncology Group (ANZGOG) in partnership with the Canadian Cancer Trials Group (CCTG) announces the local opening of theSTRIVEclinical trial– Stratification of Vulvar Squamous Cell Carcinoma by HPV and p53 status to Guide Excisionclinical trial (CCTG Protocol VU.2; ANZGOG Protocol ANZGOG2109/2021). STRIVErepresentsan important stepforward in advancing evidence-based surgical management for women diagnosed with vulvar squamous cell carcinoma (VSCC). About the STRIVE Trial STRIVE is an international, prospective, stratification study designed to refine surgical decision-making for patients withprimary vulvar squamous cell carcinoma(VSCC) based ontumourbiology. The study is led globally by the CCTG and led…

  • Medical Health Aged Care
  • 03/03/2026
  • 21:26
SAV-IOL

Lucidis® Sets High Standards in Premium Cataract Surgery with Full-Range Vision Performance

NEUCHÂTEL, Switzerland–BUSINESS WIRE– Swiss Advanced Vision announces new clinical evidence confirming the exceptional performance of its Lucidis® intraocular lens (IOL), strengthening its position as…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.